Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline ...

(CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer's disease, the ...

The Food and Drug Administration recently approved a new drug called 'Donanemab' to treat the debilitating Alzheimer's Disease. More than six million Americans nationwide struggle with the disease, ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, ...

The U.S. Food and Drug Administration has delayed action for the promising Alzheimer’s treatment donanemab, the drug manufacturer said on Friday. Eli Lilly said the FDA would wait on ruling about ...

The drug may slow the progression of Alzheimer’s disease, but it doesn’t improve the symptoms. It’s also incredibly expensive ...